首页 | 本学科首页   官方微博 | 高级检索  
     


Retrospective Review of the Use of High-Dose Cyclophosphamide,Bortezomib, Doxorubicin,and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia
Affiliation:1. Department of Lymphoma/Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, TX;2. Division of Diagnostic Imaging, Department of Diagnostic Radiology, The University of Texas M.D. Anderson Cancer Center, Houston, TX;3. Department of Stem Cell Transplantation, The University of Texas M.D. Anderson Cancer Center, Houston, TX;1. Seràgnoli Institute of Hematology, Department of Experimental, Diagnostic and Specialty Medicine, Bologna University School of Medicine, S Orsola Malpighi Hospital, Bologna, Italy;2. Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero–Universitaria Città della Salute e della Scienza di Torino, Turin, Italy;3. Department of Hematology, Ankara University School of Medicine, Ankara, Turkey;4. Hematology, Department of Translational and Precision Medicine, Azienda Ospedaliera Policlinico Umberto I, Sapienza University of Rome, Rome, Italy;5. Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece;6. Department of Immunology, Erasmus MC, Rotterdam, Netherlands;7. Department of Trials and Statistics—HOVON Data Centre, Erasmus MC Cancer Institute, Rotterdam, Netherlands;8. Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands;9. Department of Hematology, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, Netherlands;10. Dipartimento di Science Mediche Chirurgiche e Tecnologie Avanzate “GF Ingrassia”, Università degli Studi di Catania, Catania, Italy;11. Clinical Hematology and Bone Marrow Transplant Centre, S Maria della Misericordia University Hospital, DAME, University of Udine, Udine, Italy;12. Hematology Department, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy;13. Hematology and Bone Marrow Transplant Unit, ASST–Papa Giovanni XXIII, Bergamo, Italy;14. 4th Department of Internal Medicine–Hematology, Charles University Hospital and Faculty of Medicine, Hradec Kralove, Czech Republic;15. Azienda USL–IRCCS di Reggio Emilia, Reggio Emilia, Italy;p. Skane University Hospital, Lund, Sweden;q. SC Ematologia e Dipartimento di Oncologia Clinica, AO Spedali Civili, Brescia, Italy;r. University Hospital Brno, Brno, Czech Republic;s. Department of Hematology, Haga Hospital, The Hague, Netherlands;t. SC Ematologia, Azienda Ospedaliera S Croce-Carle, Cuneo, Italy;u. Department of Hematology, Radboud University Medical Centre, Nijmegen, Netherlands;v. Reparto di Ematologia con TMO, Ospedale Santa Maria della Misericordia, Perugia, Italy;w. Clinica di Ematologia, AOU Ospedali Riuniti di Ancona, Ancona, Italy;x. Division of Haematology, Grande Ospedale Metropolitano Bianchi–Melacrino–Morelli, Reggio Calabria, Italy;y. Hematology, Azienda Ospedaliera di Padova, Padua, Italy;z. Faculty of Medicine, Università degli Studi di Perugia, Perugia, Italy;11. Department of Haematology, Aarhus University Hospital, Aarhus, Denmark;12. Hematology Unit, Ospedale dell''Angelo, Mestre, Venice, Italy;13. Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, Netherlands;14. Department of Haematology, Maastricht University Medical Center, Maastricht, Netherlands;15. Wilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria;16. Ematologia e Centro Trapianti, IRCCS Ospedale Policlinico San Martino, Genoa, Italy;17. Clinical Hematology, Department of Hematology, Transfusion Medicine and Biotechnology, “Spirito Santo” Civic Hospital, Pescara, Italy;18. Department of Hematology, ZNA Stuivenberg, Antwerp, Belgium;19. Department of Internal Medicine, Amphia Hospital Breda, Breda, Netherlands;110. Department of Hematooncology, University Hospital Ostrava and University of Ostrava, Ostrava, Czech Republic;111. University Hospital and Faculty of Medicine, Hradec Kralove, Czech Republic;112. Department of Hematology, Leiden University Medical Center, Leiden, Netherlands;113. UOSD Ematologia ASL Roma 1, Rome, Italy;114. Department Oncology/Hematology, Kantonsspital, Lucerne, Switzerland;115. Department Oncology/Hematology, Kantonsspital, St Gallen, Switzerland;1p. Hematology, University Aldo Moro, Bari, Italy;1q. Department of Hematology, St Olavs Hospital and Norwegian University of Science and Technology, Trondheim, Norway;1r. Department of Haematology, University of Copenhagen, Copenhagen, Denmark;1s. Department of Medicine, Section of Hematology and Coagulation, South Elvsborg Hospital, Gothenburg, Sweden;1t. Isala Kliniek, Zwolle, Netherlands;1u. Department of Hematology, UMC Utrecht, University Utrecht, Utrecht, Netherlands;1v. Department of Hematology, Canisius–Wilhelmina Hospital, Nijmegen, Netherlands;1w. Department of Hematology, ASST Grande Ospedale Metropolitano, Niguarda, Milan, Italy;1x. Haematology, Ospedale San Francesco, Nuoro, Italy;1y. Instituto Português de Oncologia de Lisboa Francisco Gentil, IPOLFG, Lisbon, Portugal;1z. Department of Haematology, Alfred Hospital–Monash University, Melbourne, VIC, Australia;1. Division of Hematology, Mayo Clinic, Rochester, MN, USA;2. Clinical Hematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia;3. Seragnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy;4. Hematology Service, Dr Peset University Hospital, Valencia, Spain;5. School of Medicine and Dentistry, Catholic University of Valencia, Valencia, Spain;6. Department of Haematology, University College London Hospitals, London, UK;7. School of Medicine, Duke University, Durham, NC, USA;8. Clinica São Germano, São Paulo, Brazil;9. Department of Hematology-Oncology, Asklepios Tumorzentrum Hamburg, Asklepios Klinik Altona and Asklepios Klinik St Georg, Hamburg, Germany;10. Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan;11. Department of Rehabilitation Medicine, Seoul National University, Seoul, South Korea;12. Oncology Biomarker Development, Product Development, Hemtology, Genentech, South San Francisco, CA, USA;13. Research and Development, AbbVie, North Chicago, IL, USA;14. Department of Hematology, University Hospital, Nantes, France;1. Interdisciplinary Program of Marine-Bio, Electric & Mechanical Engineering, Pukyong National University, San 100, Yongdang-dong, Nam-gu, Busan 608-739, Republic of Korea;2. Dept. of Mechanical Engineering, Pukyong National University, San 100, Yongdoang-dong, Nam-gu, Busan 608-739, Republic of Korea;3. Environment & Energy Research Division, Korea Institute of Machinery and Materials, 171, Jang-dong, Yuseong-gu, Daejeon 305-343, Republic of Korea;1. İnönü University, Turgut Özal Medical Center, Adult Haematology Department, Malatya, Turkey;2. İnönü University, Faculty of Pharmacy, Department of Clinical Pharmacy, Malatya, Turkey
Abstract:
Keywords:High-risk MM  mCBAD  Multiple myeloma  Newly diagnosed MM  Relapse/refractory MM
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号